Research Alliance Corp. II Class A Common Stock
RACB
RACB was delisted on the 1st of December, 2022.
38 hedge funds and large institutions have $147M invested in Research Alliance Corp. II Class A Common Stock in 2021 Q1 according to their latest regulatory filings, with 38 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
92.76% more ownership
Funds ownership: 0% → 92.76% (+93%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$10.2M |
| 2 |
HM
HealthCor Management
New York
|
+$10.2M |
| 3 |
PA
Perceptive Advisors
New York
|
+$10.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$9.79M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$8.19M |
Top Sellers
RACB Hedge Fund Activity: Q1 2021 in Review
38 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Research Alliance Corp. II Class A Common Stock (RACB) for Q1 2021, worth a combined $147M.
Buyers outnumbered sellers: 38 funds opened new RACB positions and 0 closed out — a net gain of 38 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Bain Capital Life Sciences Investors, opening a new position worth an estimated $10.2M.
- 38 institutional investors held Research Alliance Corp. II Class A Common Stock (RACB) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $147M of Research Alliance Corp. II Class A Common Stock stock for Q1 2021.
- 38 funds opened new Research Alliance Corp. II Class A Common Stock positions in Q1 2021 and 0 closed out, a net change of +38 holders.
- The largest Research Alliance Corp. II Class A Common Stock buyer in Q1 2021 was Bain Capital Life Sciences Investors, an estimated $10.2M added.
Based on aggregated 13F filings for Q1 2021.